Malignant neoplasm of breast
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Measles
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule.
|
12610126 |
2003 |
Measles
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression.
|
15193925 |
2004 |
Autoimmune Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Signaling lymphocytic activation molecule (SLAM) family receptors have been implicated in normal immunity, immunodeficiencies and autoimmunity.
|
23731618 |
2013 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD150 transgenic (Tg) mice, which express human CD150, an entry receptor for MV, with the disrupting IFNR gene (Ifnar(-/-)), are susceptible to MV and serve as a model for MV infection.
|
24078691 |
2013 |
Autoimmune Diseases
|
0.060 |
Biomarker
|
group |
BEFREE |
Signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) can mediate the function of SLAM molecules, which have been proposed to be involved in the development of autoimmunity in mice.
|
24373350 |
2014 |
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD150 was detected in the cytoplasm, but not on the cell surface of glioma cell lines, and it was colocalized with the endoplasmic reticulum and Golgi complex markers.
|
25710480 |
2015 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) mutations in X-linked lymphoproliferative disease (XLP) lead to defective NKT cell development and impaired humoral immunity.
|
28049627 |
2017 |
Lupus Erythematosus, Systemic
|
0.090 |
Biomarker
|
disease |
BEFREE |
Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus.
|
28076903 |
2017 |
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
CD150 or CD180 crosslinking on CLL B cells alone led to activation of Akt, mTORC1, ERK1/2, p38MAPK and JNK1/2 networks.
|
28982149 |
2017 |
Lupus Erythematosus, Systemic
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
SLAMF1 levels were increased on both T cell and B cells and their differentiated subpopulations in patients with SLE.
|
29020082 |
2017 |
Lupus Erythematosus, Systemic
|
0.090 |
Biomarker
|
disease |
BEFREE |
SLAMF1 ligation in a human peripheral blood T cell-B cell culture system reduced the following in both healthy controls and patients with SLE: conjugate formation, interleukin-6 (IL-6) production by B cells, IL-21 and IL-17A production by T cells, and Ig and autoantibody production.
|
30058241 |
2019 |
Virus Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
SLAM Family Receptor Signaling in Viral Infections: HIV and Beyond.
|
31744090 |
2019 |
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.
|
26317644 |
2015 |
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.
|
26317644 |
2015 |
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.
|
26317644 |
2015 |
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.
|
22194822 |
2011 |
Lymphoproliferative Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients.
|
12629654 |
2003 |
Epstein-Barr Virus Infections
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Absence of the inhibitor SAP in XLP patients affects T/B-cell interactions induced by SLAM, leading to an inability to control B-cell proliferation caused by Epstein-Barr virus infections.
|
9774102 |
1998 |
Infection
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Activation of signaling lymphocytic activation molecule triggers a signaling cascade that enhances Th1 responses in human intracellular infection.
|
15356162 |
2004 |
Central Nervous System Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, ependymoma, and others.
|
25710480 |
2015 |
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, ependymoma, and others.
|
25710480 |
2015 |
Adult Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, ependymoma, and others.
|
25710480 |
2015 |
Childhood Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, ependymoma, and others.
|
25710480 |
2015 |
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although CD150 was not found in different regions of normal brain tissues, our immunohistochemical study revealed its expression in 77.6% of human CNS tumors, including glioblastoma, anaplastic astrocytoma, diffuse astrocytoma, ependymoma, and others.
|
25710480 |
2015 |